DE69838177D1 - Androgensyntheseinhibitoren - Google Patents

Androgensyntheseinhibitoren

Info

Publication number
DE69838177D1
DE69838177D1 DE69838177T DE69838177T DE69838177D1 DE 69838177 D1 DE69838177 D1 DE 69838177D1 DE 69838177 T DE69838177 T DE 69838177T DE 69838177 T DE69838177 T DE 69838177T DE 69838177 D1 DE69838177 D1 DE 69838177D1
Authority
DE
Germany
Prior art keywords
prostate cancer
present
benign prostatic
prostatic hypertrophy
novel compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69838177T
Other languages
English (en)
Other versions
DE69838177T2 (de
Inventor
Angela Brodie
Yangzhi Ling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Publication of DE69838177D1 publication Critical patent/DE69838177D1/de
Application granted granted Critical
Publication of DE69838177T2 publication Critical patent/DE69838177T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
DE69838177T 1997-02-05 1998-02-05 Androgensyntheseinhibitoren Expired - Lifetime DE69838177T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US795932 1991-11-15
US08/795,932 US5994334A (en) 1997-02-05 1997-02-05 Androgen synthesis inhibitors
PCT/US1998/001569 WO1998033506A1 (en) 1997-02-05 1998-02-05 Androgen synthesis inhibitors

Publications (2)

Publication Number Publication Date
DE69838177D1 true DE69838177D1 (de) 2007-09-13
DE69838177T2 DE69838177T2 (de) 2008-04-10

Family

ID=25166812

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838177T Expired - Lifetime DE69838177T2 (de) 1997-02-05 1998-02-05 Androgensyntheseinhibitoren

Country Status (11)

Country Link
US (2) US5994334A (de)
EP (1) EP1019060B1 (de)
JP (2) JP5043250B2 (de)
AT (1) ATE368466T1 (de)
AU (1) AU6045398A (de)
CA (2) CA2628607C (de)
DE (1) DE69838177T2 (de)
DK (1) DK1019060T3 (de)
ES (1) ES2290984T3 (de)
PT (1) PT1019060E (de)
WO (1) WO1998033506A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
WO2001005364A1 (en) * 1999-07-15 2001-01-25 The Procter & Gamble Company Nitrogen-containing steroid compounds and their use to regulate hair growth
US6093421A (en) * 1999-08-31 2000-07-25 Biotics Research Corporation Maca and antler for augmenting testosterone levels
CA2386095A1 (en) 1999-09-30 2001-04-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
EP1409512A1 (de) * 2000-06-27 2004-04-21 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroide - inhibitoren von c17-20-lyase und 5-alpha reductase
US6413951B2 (en) 2000-06-27 2002-07-02 Aventis Pharmaceuticals, Inc. 20-fluoro-17(20)-vinyl steroids
DE10043846A1 (de) * 2000-09-04 2002-04-04 Jenapharm Gmbh 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
DE10141984A1 (de) * 2001-08-28 2003-03-20 Jenapharm Gmbh Neue 17-Methylen-4-azasteroide
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
US20030148987A1 (en) * 2001-12-21 2003-08-07 Morris David J. Selective 11beta-HSD inhibitors and methods of use thereof
EP1624876A2 (de) * 2003-04-29 2006-02-15 The Miriam Hospital Selektive testikuläre 11beta -hsd-inhibitoren und verfahren zur verwendung davon
DK1781683T3 (da) 2004-08-24 2012-02-06 Btg Int Ltd Fremgangsmåde til fremstilling af 17-vinyl-triflater som halvfabrikata
KR101387910B1 (ko) * 2005-01-10 2014-04-25 콜텐도 인베스트 아베 당뇨병, 대사 증후군 및 다른 질환을 치료하기 위한 방법및 조성물
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2007081980A2 (en) * 2006-01-10 2007-07-19 Diobex, Inc. Methods and compositions for treating prostate cancer
BRPI0719835A2 (pt) * 2006-10-02 2014-05-06 Cortendo Invest Ab Enantiômero de cetoconazol em humanos
EP2359828A1 (de) 2007-06-06 2011-08-24 University of Maryland, Baltimore HDAC-Inhibitoren und auf Hormone zielende Arzneimittel zur Krebsbenhandlung
GB0711948D0 (en) * 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
ES2430379T3 (es) * 2007-08-24 2013-11-20 Council Of Scientific & Industrial Research Nuevos ésteres esteroideos de 17-oximino-5-androsten-3-beta-ol
US20090075964A1 (en) * 2007-09-17 2009-03-19 Human Pheromone Sciences, Inc. Fragrance compositions and other compositions which contain naturally occurring substances found in corals
WO2009129208A2 (en) * 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
US7923426B2 (en) 2008-06-04 2011-04-12 The Procter & Gamble Company Detergent composition
EP2135933B1 (de) 2008-06-20 2013-04-03 The Procter and Gamble Company Waschzusammensetzung
RU2630577C2 (ru) 2008-12-04 2017-09-11 Чунси ЮЙ Композиции интенсивного проникновения и их применение
US20110312916A1 (en) 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
MX2012002834A (es) 2009-09-11 2012-04-10 Bionature E A Ltd Uso de compuestos esteroides para trastornos inflamatorios y autoinmunitarios.
CA2782266A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
CN103124563B (zh) 2010-08-04 2016-08-10 佩尔菲丘尔制药有限公司 用于前列腺癌治疗的联合治疗
PL2709631T3 (pl) 2011-05-20 2017-07-31 Inserm - Institut National De La Santé Et De La Recherche Médicale Antagoniści receptora cb1
EP3572417A3 (de) 2011-10-14 2020-03-25 Sage Therapeutics, Inc. 3,3-disubstituierte 19-nor-pregnan verbindungen, zusammensetzungen damit und verwendungen davon
KR101352635B1 (ko) * 2011-12-29 2014-01-20 연세대학교 산학협력단 신규 혈관누출 차단제
PE20151557A1 (es) 2012-11-28 2015-11-18 Inst Nat Sante Rech Med Derivados de 3-(4'-sustituido)-bencil-eter de pregnenolona
EP2968219B1 (de) * 2013-03-14 2019-04-24 Pellficure Pharmaceuticals, Inc. Neuartige therapie gegen prostatakarzinome
EP4066841A1 (de) 2013-03-14 2022-10-05 University of Maryland, Baltimore Mittel zur androgenrezeptor-abwärtsregelung und verwendungen davon
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
AU2014256228C1 (en) 2013-04-17 2017-09-14 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
PL2986623T3 (pl) 2013-04-17 2019-04-30 Sage Therapeutics Inc 19-nor C3,3-dipodstawione steroidy C21-n-pirazolilowe i sposoby ich stosowania
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
EP3868382A1 (de) 2013-07-19 2021-08-25 Sage Therapeutics, Inc. Neuroaktive steroide, zusammensetzungen und verwendungen davon
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
PT3488852T (pt) 2013-08-23 2021-02-03 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SG10202009859YA (en) 2014-10-16 2020-11-27 Sage Therapeutics Inc Compositions and methods for treating cns disorders
NZ769042A (en) 2014-10-16 2023-12-22 Sage Therapeutics Inc Compositions and methods for treating cns disorders
LT3224269T (lt) 2014-11-27 2020-07-10 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
ES2857082T3 (es) * 2015-01-26 2021-09-28 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
CA3030413A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
CN107722101A (zh) * 2017-11-03 2018-02-23 郑州大学 甾体吡啶类衍生物及其制备方法和应用
WO2020243488A1 (en) 2019-05-31 2020-12-03 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
CN111333696B (zh) * 2020-04-07 2021-09-24 华中药业股份有限公司 一种治疗痛风的化合物及其制备方法和用途
CN114344310B (zh) * 2021-12-02 2023-10-10 华中药业股份有限公司 一种治疗痛风的药物组合物及其制备方法与用途
WO2023220117A1 (en) * 2022-05-10 2023-11-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2335616A (en) * 1941-11-06 1943-11-30 Parke Davis & Co Steroidal hormone intermediates and their preparation
US2664423A (en) * 1952-03-12 1953-12-29 Searle & Co 4-(cyclopentanopolyhydrophenanthr-17-yl) imidazoles and derivatives thereof
US2707189A (en) * 1952-09-11 1955-04-26 Upjohn Co 3-keto-17beta-acetamido-4-androstene and process
NL281305A (de) * 1961-07-24
FR1381407A (fr) * 1963-10-17 1964-12-14 Roussel Uclaf Procédé de préparation de composés tétracycliques et produits obtenus par ce procédé
US3313809A (en) * 1965-03-05 1967-04-11 Sterling Drug Inc Steroido[21, 20-d]isoxazoles
US3317520A (en) * 1965-03-05 1967-05-02 Sterling Drug Inc Steroido[20, 21-c]pyrazoles and intermediates
US5264427A (en) * 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
AU4251993A (en) * 1992-05-20 1993-12-13 Merck & Co., Inc. Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
US5620986A (en) * 1992-05-20 1997-04-15 Merck & Co., Inc. 17 urea, thiourea, thiocarbamyl and carbamyl4-azasteroid 5-reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
DE4232681C2 (de) * 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
EP0862436A1 (de) * 1995-10-19 1998-09-09 Merck & Co., Inc. 16-substituierte-6-aza-steroid 5-alpha reduktaseinhibitoren
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors

Also Published As

Publication number Publication date
JP2001510471A (ja) 2001-07-31
WO1998033506A1 (en) 1998-08-06
EP1019060B1 (de) 2007-08-01
EP1019060A4 (de) 2005-04-13
US5994334A (en) 1999-11-30
JP5043250B2 (ja) 2012-10-10
US6133280A (en) 2000-10-17
CA2628607A1 (en) 1998-08-06
ES2290984T3 (es) 2008-02-16
DK1019060T3 (da) 2007-11-12
PT1019060E (pt) 2007-10-03
JP2010024238A (ja) 2010-02-04
DE69838177T2 (de) 2008-04-10
ATE368466T1 (de) 2007-08-15
AU6045398A (en) 1998-08-25
CA2279971A1 (en) 1998-08-06
EP1019060A1 (de) 2000-07-19
CA2628607C (en) 2011-06-07
CA2279971C (en) 2011-07-12

Similar Documents

Publication Publication Date Title
DE69838177D1 (de) Androgensyntheseinhibitoren
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
CY1107721T1 (el) Παραγωγα τυροζινης
ATE196844T1 (de) Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
AP9901478A0 (en) Compounds for the treatment of ischemia.
ATE321452T1 (de) Tetracycline verbindungen zur behandlung von spezifischen krebsarten
DE69809726T2 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
PT880540E (pt) 17-beta-ciclopropil-(amino/oxi)-4-azaesteroides como inibidores activos de 5-alfa-redutase e c17-c20-liase de testosterona
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
DE3574563D1 (de) Zusammensetzungen und verbindungen zur behandlung von prostata-adenom.
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
WO2001028593A3 (en) Conjugates useful in the treatment of prostate cancer
AU2003236701A8 (en) Guanidino phenylalanin compounds used as urokinase inhibitors
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition